Management of pseudomyxoma peritonei originating from the appendix: a single-center experience
10.3969/j.issn.1000-8179.2020.09.635
- VernacularTitle: 阑尾源性腹膜假黏液瘤单中心诊疗经验
- Author:
Xichao ZHAI
1
Author Information
1. Department of Pseudomyxoma Peritonei, Aerospace Hospital
- Publication Type:Journal Article
- Keywords:
Appendiceal neoplasm;
Complication;
Pseudomyxoma;
Regional perfusion;
Treatment outcome
- From:
Chinese Journal of Clinical Oncology
2020;47(9):460-464
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical outcomes of pseudomyxoma peritonei(PMP) originating from the appendix following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: A retrospective study was carried out by analyzing clinical data of patients who diagnosed with PMP originating from appendix and had undergone CRS and HIPEC between January 2012 and December 2018. Results: A total of 604 patients had undergone 621 CRS and HIPEC procedures. The average age of the patients was 56.7 years. Of the patients, 364 (60.3%) were female and 240 (39.7%) were male. The median peritoneal carcinomatosis index (PCI) was 25.7. Of the patients, 28.5% (172/604) had undergone complete cytoreduction (CCR 0/1). In this study, the incidence of grade 3-4 adverse events was 21.7% (131/604), and the perioperative mortality rate was 0.7% (4/604). For the entire cohort, the 5-year survival rate was 53.6%. High-grade pathological subtype CCR 2/3, PCI >20, and grade 3-4 adverse events were independent predictors of a poor overall survival. Conclusions: Appendix-derived PMP is rare, and its treatment should be considered carefully. For patients who are suspected or are confirmed as PMP, early standardized CRS and HIPEC are related to a better prognosis.
